

S 2983

ADAPT for COVID Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Oct 7, 2021

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Oct 7, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/2983>

Sponsor

Name: Sen. Braun, Mike [R-IN]

Party: Republican • **State:** IN • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Oct 7, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 1645	Related bill	May 13, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Oct 7, 2021)

Accelerated Drug Approval for Prescription Therapies for Coronavirus Act or the ADAPT for COVID Act

This bill authorizes the Food and Drug Administration (FDA) to create an expedited drug approval process specifically for drugs that are currently approved for sale in certain countries (i.e., a European Economic Area member country, Australia, Canada, Israel, Japan, New Zealand, South Africa, or Switzerland) and meet certain criteria. Such criteria shall include establishing that (1) the drug is safe and effective, (2) all relevant U.S. patents or legal exclusivities have expired, and (3) the drug is intended to treat or prevent COVID-19 or another disease of epidemic potential.

The FDA must process and review an application under this bill within 180 days of submission.

Actions Timeline

- **Oct 7, 2021:** Introduced in Senate
- **Oct 7, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.